Standard BioTools Completes Microfluidics Sale To ARCHIMED, Which Renames It Biomark Scientific
The healthcare investment firm, which manages €15 billion, now owns the unit, and a new chief commercial officer has been named.
Standard BioTools, which makes instruments and consumables for researchers studying proteins and genes, said Tuesday it has completed the sale of its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The unit now operates as a standalone company named Biomark Scientific.
A new name and a new commercial chief
The closing was announced in a joint press release with ARCHIMED, furnished with the company's filing. Biomark Scientific will be an independent entity made up of the same team, the release says, with continuity promised for the products and services customers rely on.
Luke Stewart, newly appointed chief commercial officer of Biomark Scientific, called the deal an "exciting step forward for our organization." Michael Goetter of ARCHIMED said the firm is "poised to support the company in fortifying global growth."
The release describes Biomark Scientific as a provider of high-throughput, multi-assay genomics systems. Its flagship Biomark platform includes the Biomark X9 system, which the release calls the only automated PCR, qPCR and NGS library prep system on the market, using patented integrated fluidic circuits.
What Standard BioTools keeps and what it sheds
Standard BioTools sells research-use-only tools to academic institutions, cancer centers and drugmakers. Its main platforms are CyTOF for single-cell analysis, Hyperion for mapping proteins in tissue, and Biomark, the high-throughput qPCR genomics line, according to its annual report for 2025. Biomark is the business that has now moved to ARCHIMED.
The release says Biomark was previously part of Fluidigm, which was founded in 1999 and renamed Standard BioTools in 2022. It serves research institutions, public health laboratories and biobanks.
The buyer and the pending votes
ARCHIMED is a private equity firm with offices in Europe, North America and Asia, and says it manages €15 billion across its funds. Within ARCHIMED, Biomark Scientific plans to build on its technology and customer relationships while expanding into genomics, clinical research and public health.
The filing also references two other transactions: a proposed deal with Treeline Biosciences, which carries a stockholder vote, and a sale of the Mass Cytometry business to Element Biosystems. The proxy statement and prospectus for the Treeline vote were first mailed to stockholders on or about October 21.
Stockholders have the Treeline proxy statement and prospectus, mailed on or about October 21, in hand for the vote.
Sources
- 8-K Filing — STANDARD BIOTOOLS INC. (LAB) — SEC EDGAR
- Exhibit ef20084814_ex99-1.htm — STANDARD BIOTOOLS INC. 8-K exhibit — SEC EDGAR
- ARCHIMED Life Science Tools & Services Completes — globenewswire.com